NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

NCT00315380

RecruitingN/A

Sponsor: University of Pennsylvania

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome

Countries: United States, Canada, Germany, Italy, United Kingdom

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.

Parent or guardian willing to provide informed consent, if applicable

Exclusion Criteria:

\- Inability to give informed consent and to sign the consent form
Locations (13)
  • San Diego, California, United States
  • Denver, Colorado, United States
  • Boston, Massachusetts, United States
  • Rochester, Minnesota, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Salt Lake City, Utah, United States
  • Hamilton, Ontario, Canada
  • Toronto, Ontario, Canada
  • Kirchheim unter Teck, Germany
  • Florence, Italy
  • London, United Kingdom